| Name | Nimodipine |
| Description | Nimodipine (BAY-e 9736), a 1, 4-dihydropyridine calcium channel blocker, acts primarily on vascular smooth muscle cells. |
| In vivo | Nimodipine (5-20 mg/kg, SC) suppresses in a dose-related manner self-administration both of cocaine and morphine contingent upon a nose-poke response. Nimodipine (10 mg/kg, SC), an L-type dihydropyridine Ca2+ channel antagonist, exhibits to completely block the establishment of conditioning of cocaine's effects, but only partially blocks sensitization to cocaine. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | Ethanol : 4.2 mg/mL (10.04 mM), Sonication is recommended. DMSO : 130 mg/mL (310.68 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 4 mg/mL (9.56 mM), Sonication is recommended.
|
| Keywords | well-tolerated | orally | Nimodipine | Mineralocorticoid Receptor | light-sensitive | Inhibitor | inhibit | GlucocorticoidReceptor | Glucocorticoid Receptor | dihydropyridine | cerebrovascular | CalciumChannel | Calcium Channel | calcium | Ca2+ channels | Ca channels | Autophagy | AhR |
| Inhibitors Related | Stavudine | Sodium 4-phenylbutyrate | L-Ascorbic acid | Hydroxychloroquine | Guanidine hydrochloride | Taurine | Valproic Acid | Curcumin | Paeonol | Naringin | L-Ascorbic acid sodium salt | Gefitinib |
| Related Compound Libraries | Pain-Related Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Inhibitor Library | Neuroprotective Compound Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Ion Channel Targeted Library | Anti-Cancer Drug Library |